Hemorrhagic Events During Therapy With Recombinant Tissue Plasminogen Activator, Heparin, and Aspirin for Unstable Angina (Thrombolysis In Myocardial Ischemia, Phase IIIB Trial)

This publication has 18 references indexed in Scilit:

• Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK)
  Circulation, 1994
• Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators.
  Circulation, 1994
• Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial.
  Circulation, 1994
• Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia.
  Circulation, 1994
• Individual risk assessment for intracranial haemorrhage during thrombolytic therapy
  The Lancet, 1993
• Hemorrhagic Events during Therapy with Recombinant Tissue-Type Plasminogen Activator, Heparin, and Aspirin for Acute Myocardial Infarction
  Annals of Internal Medicine, 1991
• Fibrin fragment D-dimer and fibrinogen B beta peptides in plasma as markers of clot lysis during thrombolytic therapy in acute myocardial infarction
  Blood, 1990
• Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
  Journal of the American College of Cardiology, 1988
• Nonparametric Estimation from Incomplete Observations
  Journal of the American Statistical Association, 1958
• Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens
  Acta Haematologica, 1957